Literature DB >> 9516083

IGF system components as prognostic markers in breast cancer.

A V Lee1, S G Hilsenbeck, D Yee.   

Abstract

The insulin-like growth factor (IGF) family of ligands, receptors, and binding proteins can regulate breast cancer cell proliferation in vitro, and interruption of these pathways inhibits IGF-mediated cell proliferation. If the IGF family members are key regulators of breast cancer growth and progression in vivo, we would expect their expression to be an indicator of the prognosis of the disease. Thus, measurement of IGF expression may provide an indicator of the growth effect within a tumor, and provide new targets for treatment of the disease. In this review we will summarize the data generated thus far indicating that IGF family members are indicators of prognosis of breast cancer, and that measurement of the whole IGF family in concert may provide useful information for treatment strategies of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9516083     DOI: 10.1023/a:1005915420341

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  16 in total

Review 1.  IGF and insulin action in the mammary gland: lessons from transgenic and knockout models.

Authors:  D L Hadsell; S G Bonnette
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-01       Impact factor: 2.673

2.  An association between a common variant (G972R) in the IRS-1 gene and sex hormone levels in post-menopausal breast cancer survivors.

Authors:  Jing Fan; Roberta McKean-Cowdin; Leslie Bernstein; Frank Z Stanczyk; Arthur Xuejun Li; Rachel Ballard-Barbash; Anne McTiernan; Richard Baumgartner; Frank Gilliland
Journal:  Breast Cancer Res Treat       Date:  2006-06-05       Impact factor: 4.872

3.  Overexpression of insulin-like growth factor II (IGFII) in ZR-75-1 human breast cancer cells: higher threshold levels of receptor (IGFIR) are required for a proliferative response than for effects on specific gene expression.

Authors:  K Abdul-Wahab; D Corcoran; A Perachiotti; P D Darbre
Journal:  Cell Prolif       Date:  1999-10       Impact factor: 6.831

4.  Expression of nuclear insulin receptor substrate 1 in breast cancer.

Authors:  Diego Sisci; Catia Morelli; Cecilia Garofalo; Francesco Romeo; Lucio Morabito; Filomena Casaburi; Emilia Middea; Sandra Cascio; Elvira Brunelli; Sebastiano Andò; Eva Surmacz
Journal:  J Clin Pathol       Date:  2006-08-01       Impact factor: 3.411

5.  Expression of IGF-I, IGF-II, and IGF-IR in gallbladder carcinoma. A systematic analysis including primary and corresponding metastatic tumours.

Authors:  P Kornprat; P Rehak; J Rüschoff; C Langner
Journal:  J Clin Pathol       Date:  2006-02       Impact factor: 3.411

6.  ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis.

Authors:  Craig I Campbell; James J Petrik; Roger A Moorehead
Journal:  Mol Cancer       Date:  2010-09-08       Impact factor: 27.401

7.  The pleckstrin homology and phosphotyrosine binding domains of insulin receptor substrate 1 mediate inhibition of apoptosis by insulin.

Authors:  L Yenush; C Zanella; T Uchida; D Bernal; M F White
Journal:  Mol Cell Biol       Date:  1998-11       Impact factor: 4.272

Review 8.  Crosstalk between IGF1R and estrogen receptor signaling in breast cancer.

Authors:  Dedra H Fagan; Douglas Yee
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-12       Impact factor: 2.673

9.  LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival.

Authors:  Jan Dominik Kuhlmann; Heidi Schwarzenbach; Pauline Wimberger; Micaela Poetsch; Rainer Kimmig; Sabine Kasimir-Bauer
Journal:  BMC Cancer       Date:  2012-07-31       Impact factor: 4.430

10.  The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.

Authors:  Joanna Lisztwan; Astrid Pornon; Bin Chen; Shiuan Chen; Dean B Evans
Journal:  Breast Cancer Res       Date:  2008-07-08       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.